Tag: DARZALEX FASPRO®

Clinical Data Healthcare & Pharmaceuticals News Oncology

Johnson & Johnson TALVEY Multiple Myeloma Treatment Shows Unprecedented Phase 3 MonumenTAL-3 Efficacy

Johnson & Johnson Company Information

Johnson & Johnson announced positive Phase 3 MonumenTAL-3 trial data demonstrating that a TALVEY-based bispecific combination significantly reduces the risk of progression or death in earlier-line relapsed or refractory multiple myeloma.

Regulatory Approval Healthcare & Pharmaceuticals News Oncology

Johnson & Johnson Announces FDA Approval of TECVAYLI® Plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

JohnsonAndJohnson

Johnson & Johnson announced FDA approval of TECVAYLI plus DARZALEX FASPRO for relapsed/refractory multiple myeloma with unprecedented clinical data demonstrating significant improvements in progression-free survival and overall survival.